Because TMB, T-GEP, and PD-L1 expression were independent positive predictors for the response to ICIs (Cristescu et al., 2018) and elevated in EP300-mutated cancers, we expected that EP300 mutations would correlate with a higher rate of response to ICIs. The gene discussed is CD274; the disease is cancer.